Phesgo patient information leaflet

Author: rhds

August undefined, 2024

WebJun 29, 2024 · The recommended initial dose of PHESGO is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks ... WebPhesgo (‘f-ehz-go’) is a treatment which has been created to treat HER2-positive breast cancer. Phesgo is made up of two drugs, called pertuzumab (‘pert-ooz-oo-mab’) and …

Phesgo 1200 mg/600 mg solution for injection - Patient …

PHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. See more This website is dedicated to providing reliable and current medical information about treatment options, symptoms, diagnosis, and prevention. See more Support and information for people who are newly diagnosed, in treatment, years beyond treatment, or living with breast cancer. See more A national, independent, nonprofit advocacy group that is dedicated to the concerns of women and men living with metastatic breast cancer. See more An organization dedicated to critical issues in young women with breast cancer. This is a partial list of some cancer support organizations. They are not … See more WebJan 13, 2024 · A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Changes to the PIL after your medicine was packed may mean that … goundi chad

Phesgo European Medicines Agency

WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body … WebOct 9, 2024 · The most important aspect of the GMC guidance is that information about risk must be individualised for that patient. So for example, risk of cardiac events may be higher in a patient with pre-existing cardiac disease, or peripheral neuropathy may be more relevant if you are a concert pianist, as opposed to a patient who is not. WebPhesgo® contains pertuzumab, trastuzumab, and hyaluronidase-zzxf. It is best to read this information with our general information about breast cancer. These treatments belong … child of god drawings

FDA approves combination of pertuzumab, trastuzumab, and …

Patient Resources, Downloads & Helpful Links - phesgo

WebNov 1, 2024 · Phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior … WebPatient Information Leaflet: Phesgo contains sucrose which may have an effect on the control of your blood sugar if you have diabetes mellitus. If you have been told by your … child of god embroidery designWebMar 25, 2024 · This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer … gounding a gas line with a copper rod

"WebPHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). " - Phesgo patient information leaflet

Phesgo patient information leaflet

Printable Resources PHESGO® (pertuzumab / …

WebNov 16, 2024 · Neoadjuvant Treatment of Breast Cancer. Administer PHESGO every 3 weeks for 3 to 6 cycles as part of a treatment regimen for early breast cancer [see Clinical Studies (14.2)].. Refer to the prescribing information for pertuzumab, administered in combination with trastuzumab and chemotherapy, for recommended dose and dosage modifications. WebMay 3, 2024 · They're available Monday to Friday from 9 am to 5 pm on 0808 800 4040. Best wishes, Jenn. Cancer Chat moderator. Report this post. Reply. Teamtwinmuzzy. 1 posts since. 15 Apr 2024.

Did you know?

WebPhesgo and for at least 7 months after stopping treatment • Men with breast cancer or their female partner should also use effective contraception MORE INFORMATION ABOUT PHESGO More information can be found in the Patient Information Leaflet that comes in the Phesgo pack. Your nurse or doctor will be able to give you a copy of this or WebDiscontinue Phesgo in patients receiving adjuvant therapy and withhold in patients with metastatic disease for clinically significant decrease in LVEF; Embryofetal toxicity. Exposure to Phesgo can result in embryofetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal ...

WebIndications. Early Breast Cancer PHESGO TM (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for. the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part … WebRedirecting to /treatment/targeted-therapy/phesgo (308)

WebPatients under the age of 65 years, or those with private insurance plans: ... Click on the Phesgo® package insert below for reported side effects, possible drug interactions, and other Phesgo® prescribing information; … WebMar 1, 2024 · of PHESGO (600 mg pertuzumab and 600 mg trastuzumab) on your next visit may be given over 5 minutes. This maintenance dose will follow every 3 weeks. You will …

WebPHESGO can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death PHESGO can also cause …

WebJun 29, 2024 · Data showed that 85% of patients preferred Phesgo compared to standard intravenous administration South San Francisco, CA -- June 29, 2024 -- ... Phesgo Indications and Important Safety Information. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: ... gounder \u0026 associatesWebdetected in two patients, and neutralizing anti -trastuzumab antibodies were detected in one patient. The incidence of anti-pertuzumab, anti-trastuzumab, and anti-vorhyaluronidase alfa antibodies detected at any time point (including baseline) was 12.1 % (30/248), 3.2 % (8/248), and 9 % (22/245), respectively, in patients treated with Phesgo ... goundi in englishWebRoche Resources child of god got questionsWebThe Northern Cancer Alliance prioritises work to streamline and improve the cancer pathways. This ‘pathway’ typically includes the following stages: Referral into services Investigation(s) Diagnosis Treatment Follow up and living with and beyond cancer support Some of these steps will take place within the same hospital/clinical setting, some will … goundis diseaseWebPhesgo 1200 mg/600 mg/30,000 units (providing 1200 mg pertuzumab, 600 mg trastuzumab and 30,000 units hyaluronidase per 15 mL) single-dose vials: 50242-0245-xx Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. … goundrey and dewhirstWebAug 8, 2024 · Phesgo is a cancer medicine that is used alone or with other medicines to treat early-stage breast cancer. Phesgo is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). Phesgo is used for breast cancer only if your tumor tests positive for a protein called human epidermal … child of god emily crockerWebOct 13, 2024 · If Phesgo is administered during pregnancy, or if a patient becomes pregnant while receiving Phesgo or within 7 months following the last dose of Phesgo, health care providers and patients should immediately report Phesgo exposure to Genentech at 1-888-835-2555. It is unknown if Phesgo passes into breast milk or how it could affect a nursing ... child of god in hebrew